75 results about "Geographic atrophy" patented technology

An automated segmentation and identification system / method for identifying geographic atrophy (GA) phenotypic patterns in fundus autofluorescence images. A hybrid process combines a supervised pixel classifier with an active contour algorithm. A trained, machine learning model (e.g., SVM or U-Net) provides initial GA segmentation / classification, and this is followed by Chan-Vese active contour algorithm. The junctional zones of the GA segmented area are then analyzed for geometric regularity and light intensity regularity. A determination of GA phenotype is made, at least in part, from these parameters.

A method and system for detecting nascent geographic atrophy. An optical coherence tomography (OCT) volume image of a retina of a subject is received. Using a deep learning model, an output is generated using the OCT volume image in which the output indicates whether nascent geographic atrophy is detected. A map output is generated for the deep learning model using a saliency mapping algorithm, wherein the map output indicates a level of contribution of a set of regions in the OCT volume image to the output generated by the deep learning model.

The use of Gap Junction-dependent cellular modulators in the treatment or prevention of age-related macular degeneration (AMD) is disclosed, and more particularly to their use for the treatment or prevention of dry AMD (d-AMD) and to prevent progression to wet or neovascular or advanced angiogenic AMD or geographic atrophy (GA).

A method for automatic prediction of a geographic atrophy (GA) from optical coherence tomography (OCT) data of a retina of a patient includes segmenting the OCT data using a first segmentation algorithm for providing a GA segmentation of the geographic atrophy in the retina, and segmenting the OCT data for providing structure-specific segmentations of certain structures in the retina. The method further includes determining a GA contour in the retina using the GA segmentation, and for each margin point of the GA contour, providing a number of quantifiable features using the GA contour and structure-specific segmentations such that a feature vector including the quantifiable features is provided for each margin point. The method further includes providing a respective local progression rate for each of the margin points by applying a spatial regression model having as inputs the GA contour and the feature vectors for the margin points.

A method implemented by one or more computer devices includes receiving fundus autofluorescence (FAF) image data for a retina of a subject. The FAF image data includes a first FAF image associated with a first point in time. An image input for a deep learning system is generated using the FAF image data. A predicted growth output for a geographic atrophy (GA) lesion in the retina is generated using the image input via the deep learning system. The predicted growth output is associated with at least one future time point after the first time point.

Embodiments disclosed herein generally relate to predicting geographic-atrophy lesion growth and / or geographic atrophy lesion size in an eye. The predictions can be generated by processing a data object using a neural network. The data object may include a three-dimensional data object representing a depiction of at least part of the eye or a multi-channel data object representing one or more decorresponding pictions of at least part of the eye. The neural network can include a convolutional multi-task neural network that is trained to learn features that are predictive of both lesion-growth and lesion-size outputs.

The present disclosure encompasses methods of using geographic atrophy lesion characteristics.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.

Novel anti-C3 and anti-C5 antibodies capable of modulating complement activity by specifically binding to human complement factor C3, C3a, C3b, and / or C5 are provided. Also described herein are recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding an anti-C3 and / or anti-C5 antibody are provided. Also provided are methods of delivering the transgene to the retina and methods of treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration disorders by contacting retinal cells with the rAAV)

An electronic device is disclosed. The device receives retinal images and patient data corresponding to the retinal images. The device can train a first machine learning model (“model”) based on a first group of the retinal images and patient data corresponding to the first group and a second model based on a second group of the retinal images and patient data corresponding to the second group. The electronic device can generate a first prediction based on the first subset of a third group of the retinal images and a second prediction based on the second subset of the third group. After training the first model and the second model, the device can train a third model to predict a geographic atrophy progression in an eye of a patient based on the first and second predictions, the first and second subsets, and patient data corresponding to the first and second subset.

A computer-based method and system for predicting future geographic atrophy (GA) lesion growth. An optical coherence tomography (OCT) volume for a retina of a subject associated with a first point in time is received by a process over a network. A segmentation model is used to generate a segmented volume corresponding to the OCT volume, the segmented volume comprising a plurality of 3D segments. For each 3D segment of the plurality of 3D segments, a map output is generated. A set of biomarker values is computed for a corresponding set of biomarker features using the map output. A prediction system is used to generate a prediction output that predicts a progression of a GA lesion in the retina with respect to a future point in time after the first point in time using at least one of the set of biomarker values or the map output.

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.

The described invention provides method for treating a complement disorder such as age-related macular degeneration (AMD) in a subject, comprising administering a pharmaceutical composition into an affected eye of a subject by ocular injection, wherein the composition comprises a nucleic acid encoding a soluble CD59 (sCD59) protein operably linked to a promoter, wherein the nucleic acid encoding sCD59 is packaged into a delivery vector and wherein the administering results in expression and secretion of the sCD59 protein by cells of the affected eye and the expression results in treatment of affected cells in the affected eye.

Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant are provided. Also provided are methods of delivering the transgene to the retina and methods of treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration disorders by contacting retinal cells with the rAAV.

The invention relates to a C3 complement inhibition polypeptide, a preparation method thereof and application of the C3 complement inhibition polypeptide in medicine. Specifically, the invention relates to a polypeptide capable of inhibiting C3 complement, which is capable of penetrating through a cell membrane or a body tissue barrier, in particular an ocular barrier, to a site where administration is desired. The invention also relates to a preparation method of the C3 complement inhibition polypeptide and application of the C3 complement inhibition polypeptide in treatment of ophthalmic diseases, especially treatment of age-related macular degeneration (AMD) secondary geographic atrophy (GA) and the like, and belongs to the field of biological medicine.

Provided herein are systems utilizing machine learning in detecting geographic atrophy. The system can include at least one processor, a memory, and a computing platform including the at least one processor and the memory. The computing platform can be configured to receive volumetric scan images, determine a position of each of the volumetric scan images, generate, using a trained detection algorithm, a probabilistic likelihood that each scan is informative of geographic atrophy or neovascular age-related macular degeneration, include high probability scans in a dataset, determine, using the included scans in the dataset, whether geographic atrophy or neovascular age-related macular degeneration is present or likely to occur, and output, by the detection algorithm, information indicating whether or not geographic atrophy or neovascular age-related macular degeneration is present or likely to occur.

This disclosure provides a method and system for evaluating geographic atrophy (GA) using a custom machine learning model. A set of fundus autofluorescence (FAF) images of a subject is received. Input to the machine learning model is generated using multiple FAF images. The input includes a subset of features selected from a plurality of image features. The plurality of image features includes at least one of a plurality of shape features and a plurality of texture features. The selection of the subset of features from the plurality of features is based on evaluating the performance of a set of trained models used to process at least two different combinations of the plurality of features. A set of geographic atrophy (GA) progression parameters is predicted based on the input via the custom machine learning model.

Methods and systems for evaluating geographic atrophy using a customized machine learning model. A set of fundus autofluorescence (FAF) images for a subject are received. Input for the machine learning model is generated using the plurality of FAF images. The input includes a subset of features that have been selected from a plurality of features, which include a plurality of image features. The plurality of image features includes at least one of a plurality of shape features and a plurality of texture features. Selection of the subset of features from the plurality of features is based on evaluating performance of a set of trained models that are used to process at least two different combinations of the plurality of features. A set of geographic atrophy (GA) progression parameters based on the input are predicted via the customized machine learning model.

Methods and compositions for treatment of geographic atrophy are described.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

Disclosed is the use of gap junction-dependent cellular modulators in the treatment or prevention of age-related macular degeneration (AMD), more specifically, their use for the treatment or prevention of dry AMD (d-AMD) and for preventing progression to wet or neovascular or advanced vascular AMD or geographic atrophy (GA).

Avacincaptad pegol, also known under the trademarks Izervay or Zimura, is a molecule comprising an aptamer sequence and a polyethylene glycol polymer (PEG) -moiety. The aptamer sequence binds to complement C5-protein, which C5 protein is known to be involved in many eye diseases. Avacincaptad pegol is approved to treat Age-related Macular Degeneration (AMD) secondary to Geographic Atrophy (GA) and is applied by intravitreal injection into the eye. The pharmaceutical product is currently only offered as a liquid in a vial. This patent application discloses Avacincaptad in a more stable presentation, namely in a pre-filled syringe, which surprisingly results in very significantly improved stability of the product.

To provide compositions and methods for treating retinal diseases or disorders using RPE cells.SOLUTION: The present invention provides a pharmaceutical composition for treating or slowing the progression of a retinal disease or disorder in a subject, comprising a therapeutically effective amount of retinal pigment epithelium (RPE) cells. The therapeutically effective amount of RPE cells is about 50,000 and 5,000,000 cells. The composition is formulated for implantation to a region covering the geographic atrophy (GA) lesion or a region covering the fovea in a subject.SELECTED DRAWING: None

A method and system for evaluating geographic atrophy in a retina. A set of fundus autofluorescence (FAF) images of the retina is received. An input is generated for a machine learning system using the set of fundus autofluorescence images. A lesion area is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the set of fundus autofluorescence images. A lesion growth rate is predicted, via the machine learning system, for the geographic atrophy lesion in the retina using the input.

A method, system, and computer program product for evaluating a geographic atrophy lesion. An image of a geographic atrophy (GA) lesion is received. A first set of values is determined for a set of shape features using the image. A second set of values is determined for a set of textural features using the image. GA progression for the GA lesion is predicted using the first set of values and the second set of values.

This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotrophic lateral sclerosis, autoimmune blistering disease, bullous pemphigoid, geographic atrophy, or Guillain-Barre Syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of the compound.

The present disclosure relates to the treatment and / or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides novel therapeutic antibodies that target components of the alternative pathway of the complement activation system, including complement factor H-related (CFHR) 4.

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.